Quality assessment of clinical practice guidelines or consensus for pancreatic diseases in China from 2016 to 2021
10.3760/cma.j.cn115667-20220304-00028
- VernacularTitle:2016年至2021年中国胰腺疾病临床实践指南或共识的质量评价
- Author:
Yingqin LYU
1
;
Yuqing CHEN
;
Xinyi ZENG
;
Han ZHANG
;
Huifang XIA
;
Xinxin PU
;
Kang ZOU
;
Yan PENG
;
Xiaowei TANG
Author Information
1. 西南医科大学附属医院消化内科，泸州 646000
- Keywords:
Pancreas;
Disease;
Guidebooks;
Consensus;
AGREE-China;
RIGHT;
Quality assessment
- From:
Chinese Journal of Pancreatology
2022;22(3):178-184
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the methodological quality and reporting quality of clinical practice guidelines or consensuses in the field of Chinese pancreatic diseases from 2016 to 2021, and provide reference for formulating clinical practice guidelines and consensuses in this field.Methods:VIP, Wanfang , CNKI and CBM databases were searched for articles published from January 2016 to March 2021. The main index terms were " pancreas" , " guideline" , " consensus" , and the supplementary index terms were " pancreatitis" , " pancreatic cancer" , " pancreatic head cancer" . Two researchers independently selected the literature. The appraisal of guidelines for research and evaluation (AGREE-China) was utilized to assess the methodological quality of the guidelines or consensuses, and the reporting items for practice guidelines in healthcare (RIGHT) tool was used to assess the reporting quality.Results:A total of 14 literature were included, including 7 literature on pancreatic cancer, 3 literature on acute pancreatitis, 1 literature on chronic pancreatitis and 3 literature on others. The results of the assessment by the AGREE-China tool showed that there were no document with a total score greater than or equal to 60.0 points, two with 40.0 to 59.9 points, eleven with 20.0 to 39.9 points, and one with less than 20.0 points. Among the results of RIGHT list, basic information was reported the highest(72.62%) and funding and declaration was the lowest(0).Conclusions:The methodological and reporting quality of the guidelines or consensuses on pancreatic disease in China from 2016 to 2021 are generally not high. In the process of developing domestic guidelines or consensuses on pancreatic diseases, the guideline developer should refer to AGREE-China and RIGHT to improve the quality of clinical practice guidelines or consensuses.
